Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
3.4.2024 13:55:00 EEST | Business Wire | Press release
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.
Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors. The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
“The limitations of current checkpoint therapies are evident, as they don’t fully target the diverse spectrum of mechanisms associated with non-responsiveness and treatment resistance,” said Dr. Ali H. Munawar, CEO of Conformation-X Therapeutics.
Despite the pivotal role of PD-1/PD-L1 inhibitors in cancer immunotherapy, several peer-reviewed clinical studies have shown that the overall response rate across various cancers remains at or below 20%. Patients facing resistance to conventional checkpoint therapies encounter a range of challenges. This includes tumors that inherently possess low immunogenicity, are less likely to trigger an immune response, and immune exclusion, which restricts immune cells from the tumor microenvironment (TME). Moreover, complex genetic landscapes featuring oncogenic drivers and epigenetic modifications further contribute to immune evasion and influence treatment outcomes.
Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts.”
The recent capital infusion accelerates the company towards translational studies of its lead asset and facilitates the expansion of its pipeline. The company's pipeline encompasses diverse drug target classes, extending beyond the current landscape of immune checkpoints to include novel soluble and epigenetic checkpoints while continuing to innovate within the B7-family of receptors.
“Achieving selective therapeutic targeting of HHLA2 demonstrates our team’s profound understanding of its intricate structure-function relationship and the critical role that HHLA2 plays in tumor immune evasion. Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.
About Conformation-X Therapeutics
Conformation-X utilizes a proprietary discovery platform enriched by structural insights to pioneer therapeutics with innovative mechanisms of action. The company is developing a diverse portfolio of immunotherapies that activate both the innate and adaptive arms of the immune system. The company’s premier preclinical asset includes a potent HHLA2-inhibitor that selectively restores its immune-suppressing effect with application in PD1/PDL1-negative cancers. To learn more visit www.conformationx.com.
Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.
About Pledge Therapeutics
Pledge Therapeutics is headquartered in Greater Boston with a second R&D branch in Leuven, Belgium. Pledge harnesses a state-of-the-art platform that merges structure-based drug design with biophysics, facilitating breakthroughs in the design of treatments for challenging therapeutic targets.
Pledge is grounded in a collaborative ethos, drawing on a network of experienced life sciences entrepreneurs, clinicians, and discovery scientists. Under its management umbrella, Pledge unites two independent biotech ventures: Orthogon Therapeutics, which specializes in antiviral treatments, and Conformation-X, dedicated to advancements in immune-oncology. This integrated model reinforces Pledge’s mission to revolutionize patient care across diverse therapeutic areas. More info on www.pledge-tx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403623298/en/
Contact information
Media
Ali H. Munawar, Ph.D.
amunawar@conformationx.com
1-339-502-8643
Maria Martin
mmartin@pledge-tx.com
1-339-502-8630
Krishna Kandala
kkandala@pledge-tx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
comforte Launches TAMUNIO Assure to Modernize HPE Nonstop Cryptography for the Post-Quantum Era2.6.2026 11:10:00 EEST | Press release
comforte AG, a global leader in data-centric security for HPE Nonstop environments, today announced the launch of TAMUNIO Assure, a purpose-built solution for HPE Nonstop that helps organizations modernize cryptographic security without application rewrites or disruption to mission-critical systems. TAMUNIO Assure helps organizations enhance SSH & SSL/TLS security, centralizing keys, credentials, certificates, and secrets, and automating certificate and key lifecycle management across HPE Nonstop systems. The result is stronger security, more cost-effective operations, and a quantum-safe security posture without rewriting critical applications or introducing high-risk platform changes. The crypto operating model for HPE Nonstop is changing HPE Nonstop systems power some of the world’s most demanding transaction environments, including payment networks and financial infrastructure, where continuous availability is essential. As security and compliance requirements evolve, organizations
NIPPON KINZOKU Launches Sample Supply of “Internally Polished Capillary Tubes” for High-Performance Analytical Instruments2.6.2026 11:01:00 EEST | Press release
NIPPON KINZOKU CO., LTD. (TOKYO: 5491) (Headquarters: Minato-ku, Tokyo) announces the launch of a sample supply system for its "Internally Polished Capillary Tubes." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602111592/en/ Cross-section of the tube after polishing These tubes feature significantly enhanced internal smoothness in ultra-small sizes, realized through the development of the company’s proprietary internal polishing technology. We are currently proceeding with the design and construction of manufacturing equipment, aiming for mass production within fiscal year 2027. Background: Rising Demand for "Ultra-Small Diameter x Ultra-Smooth Internal Surfaces" We have previously developed high-precision, small-diameter tubes made of austenitic stainless steel with an internal diameter (ID) of 0.50mm and internal surface roughness of ≤ 0.5μm, which have been highly evaluated across various industries. In recent years,
OPEX ® Honored with Warehouse Automation Solution of the Year Award for First-of-its-Kind Cold Storage Solution2.6.2026 11:00:00 EEST | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has been honored by Logistics Matters magazine with the 2026 Warehouse Solution of the Year Award. OPEX was recognized for the company’s first-of-its-kind, multi-temperature zone, multi-deep cold storage solution for automated warehouse fulfillment systems, enabled through a strategic technology partnership with cold chain commerce innovator Peltier. The collaboration introduced advanced, multi-temperature capabilities to OPEX’s industry-leading Perfect Pick® and Infinity® automated storage and retrieval systems (AS/RS) through the addition of the Peltier Tote™. “We’re deeply honored to receive such distinguished recognition by Logistics Matters magazine,” said Monty McVaugh, Head of Product, Warehouse Automation, OPEX. “By integrating Peltier’s tote technology into the existing framework of Perfect Pick and Infinity, OPEX can deliver a flexible,
Smartstream Launches Smart Agents for Back-Office Operations, Proven Across Tier 1 Pilots2.6.2026 10:55:00 EEST | Press release
Smartstream, a trusted data solutions provider for leading global financial institutions and enterprises, today announced the availability of Smart Agents, its agentic AI solution designed for bank operations. Proven in Tier 1 pilot deployments and natively integrated with Smart Reconciliations, it can be deployed immediately without changes to client infrastructure and is purpose built for regulated environments. Financial institutions dedicate up to 70% of operational effort to exception workflows fragmented across disconnected systems. Smart Agents transforms this dynamic: instead of analysts going to the data, the data comes to them, surfacing only the workflow steps that require human action, while everything else is handled autonomously end-to-end. This includes counterparty and internal communications that eliminate the manual effort consuming significant operational time. Thomas Steinborn, Chief Product and Technology Officer, Smartstream, commented: “The Pilot results demonstr
ThetaRay Gamifies Financial Defense at Money20/20 Europe with a Compliance Twist on “Where’s Waldo”2.6.2026 10:30:00 EEST | Press release
ThetaRay, a leader in AI infrastructure for financial crime compliance, today unveiledSpot The Money Mule at Money20/20 Europe. The high-speed online game is a compliance twist on "Where’s Waldo" for the AI age, designed to bridge the gap between complex banking infrastructure and the public’s role in stopping global crime. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602629234/en/ The game challenges players to find a money mule hidden in plain sight across five buzzing everyday scenes, from the morning rush at an airport to the vibrant rows of a Dutch Tulip Festival. “In the AI age, the most dangerous threats are those that blend perfectly into the speed of our digital lives,” said Garima Chaudhary, VP Financial Crime & Compliance AI at ThetaRay. “In the game, you look for a 'Known' face. In the real world, there is no obvious profile. While humans struggle to spot one person in a crowd, our AI monitors behavioral bas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom